ArticleOncotarget2016
RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.Frontiers in immunology · 2026Review
- Expression of FoxP3 in oral squamous cell carcinoma and its biological significance.Discover oncology · 2025Article
- A model based on immunogenic cell death-related genes predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma.Translational cancer research · 2024Article
- The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer.International journal of general medicine · 2024Article
- Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer.Viruses · 2023Article
- Review
- Article
- Effect of RUNX1/FOXP3 axis on apoptosis of T and B lymphocytes and immunosuppression in sepsis.Open medicine (Warsaw, Poland) · 2023Article
- Review
- The expression landscape of FOXP3 and its prognostic value in breast cancer.Annals of translational medicine · 2022Article
- Comprehensive Analysis of Prognostic and immune infiltrates for FOXPs Transcription Factors in Human Breast Cancer.Scientific reports · 2022Article
- Forkhead box P3 promotes breast cancer cell apoptosis by regulating programmed cell death 4 expression.Oncology letters · 2020Article
- RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.Journal of cellular physiology · 2020Article
- Article
- Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo.Journal of experimental & clinical cancer research : CR · 2020Article
- Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.Molecular cancer · 2019Review
- RUNX1 maintains the identity of the fetal ovary through an interplay with FOXL2.Nature communications · 2019Article
- RUNX1-dependent mechanisms in biological control and dysregulation in cancer.Journal of cellular physiology · 2019Review
- RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.Journal of translational medicine · 2019Article
- Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor.Molecular cancer research : MCR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Runx1 participation in epithelial mammary cells is still under review. Emerging data indicates that Runx1 could be relevant for breast tumor promotion. However, to date no studies have specifically evaluated the functional contribution of Runx1 to control gene expression in mammary epithelial tumor cells. It has been described that Runx1 activity is defined by protein context interaction. Interestingly, Foxp3 is a breast tumor suppressor gene. Here we show that endogenous Runx1 and Foxp3 physically interact in normal mammary cells and this interaction blocks Runx1 transcriptional activity. Furthermore we demonstrate that Runx1 is able to bind to R-spondin 3 (RSPO3) and Gap Junction protein Alpha 1 (GJA1) promoters. This binding upregulates Rspo3 oncogene expression and downregulates GJA1 tumor suppressor gene expression in a Foxp3-dependent manner. Moreover, reduced Runx1 transcriptional activity decreases tumor cell migration properties. Collectively, these data provide evidence of a new mechanism for breast tumor gene expression regulation, in which Runx1 and Foxp3 physically interact to control mammary epithelial cell gene expression fate. Our work suggests for the first time that Runx1 could be involved in breast tumor progression depending on Foxp3 availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.